ストックスクリーナーアプリを入手
132.67
1.71%
-1.39
前日終値:
$134.06
開ける：
$130
24時間の取引高:
2.76M
Relative Volume:
0.44
時価総額：
$163.92B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
19.56
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
+0.09%
1か月 パフォーマンス:
-6.90%
6か月 パフォーマンス:
+10.88%
1年 パフォーマンス:
+34.24%
1日の値動き範囲:
$129.00
$133.34
1週間の範囲:
$129.00
$136.75
52週間の値動き範囲:
$96.19
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
132.06 | 166.40B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
959.00 | 869.41B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
222.08 | 535.63B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
201.38 | 358.55B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
182.52 | 283.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.08 | 277.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Needham Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $170 - Moomoo
Gilead Sciences, Inc. (NASDAQ:GILD) Plans Quarterly Dividend of $0.82 - MarketBeat
Gilead (GILD) Q1 2026 Earnings Call Transcript - The Globe and Mail
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $157 to $160 - 富途牛牛
Gilead Sciences Forecasts $1 Billion in Sales for Twice-Yearly PrEP Injection Yeztugo - geneonline.com
Gilead sets blockbuster bar for Yeztugo’s first full year on the market - BioSpace
Morgan Stanley lowers Gilead Sciences stock price target on guidance update - Investing.com Canada
Gilead Sciences (GILD) Stock Drops Despite Q1 Beat on Massive Acquisition Charges - Blockonomi
Gilead Sciences (GILD) Stock Falls After Earnings as Acquisition Costs Hit Guidance - CoinCentral
Gilead Sciences, Inc. $GILD Holdings Decreased by GRIMES & Co WEALTH MANAGEMENT LLC - MarketBeat
Gilead Sciences Announces First Quarter Financial Results - BioSpace
Gilead Sciences (GILD) Reports Strong Q1 2026 Earnings and Raises Sales Guidance - GuruFocus
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook - TradingView
Gilead Sciences, Inc. (GILD.US) 1Q Net Profit +54% YoY to USD2.021B, Sees FY Loss Due to Acquisitions - AASTOCKS.com
Gilead Q1 2026 slides: HIV surge drives guidance raise despite M&A costs - Investing.com
Earnings call transcript: Gilead Sciences beats Q1 2026 forecasts, stock dips - Investing.com Canada
Gilead Sciences Q1 Earnings Call Highlights - MarketBeat
Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results - MarketBeat
How Gilead Sciences Inc. (GILD) Affects Rotational Strategy Timing - Stock Traders Daily
Gilead Sciences (GILD) Reports Q1 Earnings Beat, Updates EPS Gui - GuruFocus
Gilead Sciences falls 4% as acquired IPR&D charges impact full-year earnings guidance - Investing.com Nigeria
Gilead Sciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:GILD) 2026-05-07 - Seeking Alpha
Gilead slips despite Q1 beats as it now expects 2026 loss per share - MSN
Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. - Barron's
Will Anito-Cel Rescue Gilead’s Cell Therapy Business? - Citeline News & Insights
Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance Singapore
Gilead Lifted Its Sales View, But 2026 Earnings Took A Hit - Finimize
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions - Reuters
Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance UK
Gilead Sciences expects loss this year on acquired R&D expenses - MSN
Gilead earnings show HIV drugs continue to shine. Why the guidance cut? - MSN
Gilead raises 2026 sales forecast, flags profit hit from acquisitions - 93.3 The Drive
Gilead Sciences (NASDAQ:GILD) Issues FY 2026 Earnings Guidance - MarketBeat
Earnings snapshot: Gilead beats Q1 estimates but guides for FY26 loss - MSN
Gilead Sciences Inc (NASDAQ:GILD) Beats Q1 Estimates But Stock Falls on Hefty Acquisition Costs and Revised Loss Guidance - ChartMill
Gilead Sciences Expects Loss This Year on Acquired R&D Expenses - WSJ
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue - StockStory
GILEAD SCIENCES ($GILD) Releases Q1 2026 Earnings - Quiver Quantitative
Gilead Sees 2026 Loss on $11.5 Billion in Deal-Related Costs - Bloomberg.com
Gilead Sciences Q1 Adjusted Earnings, Revenue Rise; Lowers Full-Year EPS Guidance - marketscreener.com
(GILD) Gilead Sciences Now Expects 2026 Adjusted Loss Per Share Range $1.05-$0.65, vs. FactSet Est for EPS of $8.55 - marketscreener.com
Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions By Reuters - Investing.com
Gilead Tumbles On Mixed Guidance Update Amid Recent M&A Frenzy - Investor's Business Daily
Earnings Flash (GILD) Gilead Sciences, Inc. Posts Q1 Adjusted EPS $2.03 per Share - marketscreener.com
Earnings Flash (GILD) Gilead Sciences Posts Q1 Revenue $7B, vs. FactSet Est of $6.91B - marketscreener.com
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights - GlobeNewswire Inc.
Gilead earnings up next: Can Yeztugo deliver after buyout blitz? By Investing.com - Investing.com Nigeria
Gilead earnings up next: Can Yeztugo deliver after buyout blitz? - Investing.com
Gilead Accuses Pharmacies Of Selling Counterfeit HIV Drugs - Law360
Gilead Sciences shares decline 1.36% ahead of first quarter earnings - Mint
Gilead guides for earnings loss after M&A mania, but bumps up sales expectations - FirstWord Pharma
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.40%
1.39%
大文字化:
|
ボリューム (24 時間):